Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
OrganonOGN +0.15%71 EV-to-EBIT is 10.70 as of Jul. 21, 2026, which is 14% above its 10-year median of 9.42. GuruFocus rates OGN with a GF Score™ of 71/100 and a GF Value™ of $14.53 (Fairly Valued). The stock has 10 warning signs investors should review. Among 690 Drug Manufacturers companies, Organon ranks better than 68.12% on this metric.
EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Organon's Enterprise Value is $11,001 Mil.
Organon's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 was $1,028 Mil. Therefore, Organon's EV-to-EBIT for today is 10.70.
The historical rank and industry rank for Organon's EV-to-EBIT or its related term are showing as below:
OGN'
s EV-to-EBIT Range Over the Past 10 Years
Min: 3.74 Med: 9.42 Max: 11.64
Current: 10.7
During the past 8 years, the highest EV-to-EBIT of Organon was 11.64. The lowest was 3.74. And the median was 9.42.
OGN's EV-to-EBIT is ranked better than 68.12% of 690
companies
in the Drug Manufacturers industry
Industry Median: 15.84
vs OGN: 10.70
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Organon's Enterprise Value for the quarter that ended in Mar. 2026 was $9,026 Mil.
Organon's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $1,028 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Organon EV-to-EBIT Related Terms
Organon EV-to-EBIT Historical Data
* Premium members only.
The historical data trend for Organon's EV-to-EBIT can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - General subindustry, Organon's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Organon EV-to-EBIT vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Organon's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Organon's EV-to-EBIT falls into.
Organon's current Enterprise Value is $11,001 Mil.
Organon's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $1,028 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Organon (OGN) has a EV-to-EBIT of 10.70 as of Jul. 21, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Organon and its competitors. This is 14% above median its historical median of 9.42. Over the past decade, Organon's EV-to-EBIT has ranged from 3.74 to 11.64. According to the industry distribution chart, Organon ranks #220 out of 690 companies in the Drug Manufacturers industry, placing it in the top 31.9%.
Is Organon's EV-to-EBIT too high?
Organon's current EV-to-EBIT of 10.70 is 14% above median its 10-year median of 9.42. Over the past 10 years, this metric has ranged from a low of 3.74 to a high of 11.64. The Drug Manufacturers industry median EV-to-EBIT is 15.84. Organon's value of 10.70 is 32.4% below this industry median. Based on the distribution chart, Organon ranks #220 out of 690 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Organon has a GF Score™ of 71/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Organon's EV-to-EBIT compare to AMRN and SCLX?
According to the Drug Manufacturers industry distribution chart, Organon ranks #220 out of 690 companies for EV-to-EBIT. This puts Organon in the upper half of its industry. The industry median EV-to-EBIT is 15.84. Organon's value of 10.70 is 32.4% below this benchmark. Historically, Organon's own EV-to-EBIT has ranged from 3.74 to 11.64 over the past decade. While the company's 10-year median is 9.42 vs. the industry median of 15.84, Organon has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Drug Manufacturers company?
The median EV-to-EBIT among Drug Manufacturers companies is 15.84, based on 690 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Organon's current EV-to-EBIT of 10.70 is 32.4% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Organon and its competitors. For the Drug Manufacturers industry, the median EV-to-EBIT is 15.84 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Organon's current EV-to-EBIT is 10.70, which is 14% above median its own 10-year median of 9.42. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Organon stock overvalued right now?
Based on GuruFocus' analysis, Organon (OGN) is currently considered Fairly Valued. The stock's GF Value™ is $14.53, compared to a current price of $13.51 — trading 7% below its estimated fair value. The current EV-to-EBIT is 10.70, which is 14% above median its 10-year median of 9.42 and 32.4% below the Drug Manufacturers industry median of 15.84. Organon's overall GF Score™ is 71/100 with 10 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For Organon (OGN), the current EV-to-EBIT is 10.70 as of Jul. 21, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Organon (OGN) Overvalued in 2026?
Based on GuruFocus' analysis, Organon stock appears to be undervalued.
The current stock price of $13.51 is trading 7% below its estimated GF Value™ of $14.53.
GuruFocus considers Organon to be Fairly Valued.
Key valuation signals for OGN:
EV-to-EBIT: 10.70 (14% above median its 10-year median of 9.42)
GF Value™: $14.53 vs. price of $13.51 (7% below fair value)
Industry Position: 32.4% below the Drug Manufacturers median (#220 of 690)
No single metric tells the full story. See the OGN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Organon & Cois a globalised healthcare company with a mission to deliver impactful medicines and solutions for a healthier every day. Its operations include the following product portfolios: Women's Health: Itbwomen's health portfolio of products is sold by prescription mainly in two therapeutic areas: contraception, with key brands such as Nexplanon, and fertility, with key brands such as Follistim. other women's health products include the Jada, which is intended to provide control and treatment of abnormal postpartum uterine bleeding or hemorrhage when conservative management is warranted. The General Medicines portfolio includes biosimilars and established brands. Companies' current biosimilars portfolio spans across immunology and oncology-related treatments.
71GF Score
Get the complete analysis for OGN
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
OGN has been successfully added to your 
